Drug intelligence / Profile preview

SK-1011

Development stage: Unknown
Lead developer: Guangzhou JOYO Pharma Co., Ltd
Modality: Small Molecules
Administration: Oral

Overview

SK-1011 is an orally administered small molecule calpain inhibitor being developed by Sanwa Kagaku Kenkyusho for the treatment of age-related macular degeneration (AMD), specifically subfoveal choroidal neovascularization (CNV). Calpains are a family of calcium-dependent cysteine proteases that play a role in various pathological processes, including neurodegeneration and angiogenesis. By inhibiting calpain activity, SK-1011 aims to suppress the formation of new, leaky blood vessels in the retina and protect retinal cells from damage. It has been evaluated in Phase 2 clinical trials in Japan, where it was administered at a dose of 60 mg twice daily.

Targets

CAPN (Schistosoma calpain large subunit family)

Beyond the preview

Go deeper on SK-1011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK-1011.

Explore the full profile